NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+11.12%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.52B
AUM Growth
+$1.52B
(-5.4%)
Cap. Flow
-$324M
Cap. Flow
% of AUM
-21.4%
Top 10 Holdings %
Top 10 Hldgs %
55.26%
Holding
50
New
2
Increased
13
Reduced
10
Closed
3
Top Buys
| 1 |
LanzaTech
LNZA
|
$61.4M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$12M |
| 3 |
Insmed
INSM
|
$8.51M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$5.83M |
| 5 |
SPRB
Spruce Biosciences, Inc. Common Stock
SPRB
|
$4.88M |
Top Sells
| 1 |
Stryker
SYK
|
$195M |
| 2 |
Steris
STE
|
$86.4M |
| 3 |
Boston Scientific
BSX
|
$62.6M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$52.6M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$15.2M |
Sector Composition
| 1 | Healthcare | 57.28% |
| 2 | Technology | 25.52% |
| 3 | Financials | 5.42% |
| 4 | Communication Services | 4.36% |
| 5 | Industrials | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ASML
ASML
$292B
| $154M | 10.18% | 226,770 | – | – |
|
2
Salesforce
CRM
$245B
| $116M | 7.63% | 578,500 | – | – |
|
|
CYT
3
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $113M | 7.45% | 3,940,413 | – | – |
|
4
Brookfield
BN
$98.3B
| $82.1M | 5.42% | 2,508,830 | – | – |
|
5
Corcept Therapeutics
CORT
$7.35B
| $73.2M | 4.83% | 3,377,768 | – | – |
|
6
TSMC
TSM
$1.2T
| $66.1M | 4.36% | 710,780 | – | – |
|
7
Cable One
CABO
$909M
| $66.1M | 4.36% | 94,103 | – | – |
|
|
8
LanzaTech
LNZA
$49.1M
| $61.4M | 4.05% | +15,814,845 | New | +$61.4M |
|
|
CTLT
9
DELISTED
CATALENT, INC.
CTLT
| $54.7M | 3.61% | 832,878 -800,000 | -49% | -$52.6M |
|
10
Alibaba
BABA
$322B
| $51.2M | 3.38% | 500,827 | – | – |
|
11
Disc Medicine
IRON
$2.07B
| $49.6M | 3.27% | 2,340,772 | – | – |
|
12
Apple
AAPL
$3.45T
| $48.7M | 3.21% | 295,280 -73,824 | -20% | -$12.2M |
|
13
Edgewise Therapeutics
EWTX
$1.51B
| $40.5M | 2.67% | 6,071,703 | – | – |
|
14
Mirum Pharmaceuticals
MIRM
$3.71B
| $40.5M | 2.67% | 1,684,193 | – | – |
|
15
Arcellx
ACLX
$3.85B
| $37.7M | 2.49% | 1,225,000 -259,020 | -17% | -$7.98M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $35.7M | 2.36% | 367,380 +49,680 | +16% | +$4.83M |
|
|
VECT
17
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $30.7M | 2.03% | 3,610,461 +270,977 | +8% | +$2.31M |
|
18
Vaxcyte
PCVX
$4B
| $27.9M | 1.84% | 745,000 +20,000 | +3% | +$750K |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $27.3M | 1.8% | 134,986 -75,014 | -36% | -$15.2M |
|
20
Alnylam Pharmaceuticals
ALNY
$58.5B
| $23.7M | 1.56% | 118,383 +6,383 | +6% | +$1.28M |
|
21
Amicus Therapeutics
FOLD
$2.34B
| $23.2M | 1.53% | 2,095,900 | – | – |
|
|
22
Insmed
INSM
$28.8B
| $22.8M | 1.51% | 1,339,304 +499,304 | +59% | +$8.51M |
|
|
OKUR
23
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $20.5M | 1.35% | 3,430,377 | – | – |
|
|
BPMC
24
DELISTED
Blueprint Medicines
BPMC
| $20.2M | 1.33% | 448,804 +78,804 | +21% | +$3.55M |
|
|
25
Crinetics Pharmaceuticals
CRNX
$2.92B
| $17.7M | 1.17% | 1,100,000 +362,943 | +49% | +$5.83M |
|